PURPOSE: We assessed long-term mortality and hospitalisation in patients with severe sepsis resuscitated withhydroxyethyl starch (HES) or Ringer's acetate. METHODS: This was an investigator-initiated, parallel-grouped, blinded randomised trial using computer-generated allocation sequence and centralised allocation data that included 804 patients with severe sepsis needing fluid resuscitation in 26 general intensive care units (ICUs) in Scandinavia. Patients were allocated to fluid resuscitation using either 6% HES 130/0.42 or Ringer's acetate during ICU admission. We assessed mortality rates at 6 months, 1 year and at the time of longest follow-up and days alive and out of hospital at 1 year. RESULTS: The vital status of all patients was obtained at a median of 22 (range 13-36) months after randomisation. Mortality rates in the HES versus Ringer's groups at 6 months were 53.3 (212/398 patients) versus 47.5% (190/400) [relative risk 1.12; 95% confidence interval (CI) 0.98-1.29; P = 0.10], respectively; at 1 year, 56.0 (223/398) versus 51.5% (206/400) (1.09; 95% CI 0.96-1.24; P = 0.20), respectively; at the time of longest follow-up, 59.8 (238/398) versus 56.3% (225/400) (1.06; 95% CI 0.94-1.20; P = 0.31), respectively. Percentage of days alive and out of hospital at 1 year in the HES versus Ringer's groups was 24 (0-87 days) versus 63% (0-90) (P = 0.07). CONCLUSIONS: The long-term mortality rates did not differ in patients with severe sepsis assigned to HES 130/0.42 versus Ringer's acetate, but we could not reject a 24% relative increased or a 4% relative decreased mortality at 1 year with HES at the 95% confidence level.
RCT Entities:
PURPOSE: We assessed long-term mortality and hospitalisation in patients with severe sepsis resuscitated with hydroxyethyl starch (HES) or Ringer's acetate. METHODS: This was an investigator-initiated, parallel-grouped, blinded randomised trial using computer-generated allocation sequence and centralised allocation data that included 804 patients with severe sepsis needing fluid resuscitation in 26 general intensive care units (ICUs) in Scandinavia. Patients were allocated to fluid resuscitation using either 6% HES 130/0.42 or Ringer's acetate during ICU admission. We assessed mortality rates at 6 months, 1 year and at the time of longest follow-up and days alive and out of hospital at 1 year. RESULTS: The vital status of all patients was obtained at a median of 22 (range 13-36) months after randomisation. Mortality rates in the HES versus Ringer's groups at 6 months were 53.3 (212/398 patients) versus 47.5% (190/400) [relative risk 1.12; 95% confidence interval (CI) 0.98-1.29; P = 0.10], respectively; at 1 year, 56.0 (223/398) versus 51.5% (206/400) (1.09; 95% CI 0.96-1.24; P = 0.20), respectively; at the time of longest follow-up, 59.8 (238/398) versus 56.3% (225/400) (1.06; 95% CI 0.94-1.20; P = 0.31), respectively. Percentage of days alive and out of hospital at 1 year in the HES versus Ringer's groups was 24 (0-87 days) versus 63% (0-90) (P = 0.07). CONCLUSIONS: The long-term mortality rates did not differ in patients with severe sepsis assigned to HES 130/0.42 versus Ringer's acetate, but we could not reject a 24% relative increased or a 4% relative decreased mortality at 1 year with HES at the 95% confidence level.
Authors: Matti Reinikainen; Sari Karlsson; Tero Varpula; Ilkka Parviainen; Esko Ruokonen; Marjut Varpula; Tero Ala-Kokko; Ville Pettilä Journal: Intensive Care Med Date: 2010-02-09 Impact factor: 17.440
Authors: Ryan Zarychanski; Ahmed M Abou-Setta; Alexis F Turgeon; Brett L Houston; Lauralyn McIntyre; John C Marshall; Dean A Fergusson Journal: JAMA Date: 2013-02-20 Impact factor: 56.272
Authors: John A Myburgh; Simon Finfer; Rinaldo Bellomo; Laurent Billot; Alan Cass; David Gattas; Parisa Glass; Jeffrey Lipman; Bette Liu; Colin McArthur; Shay McGuinness; Dorrilyn Rajbhandari; Colman B Taylor; Steven A R Webb Journal: N Engl J Med Date: 2012-10-17 Impact factor: 91.245
Authors: R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno Journal: Intensive Care Med Date: 2013-01-30 Impact factor: 17.440
Authors: Bertrand Guidet; Olivier Martinet; Thierry Boulain; Francois Philippart; Jean François Poussel; Julien Maizel; Xavier Forceville; Marc Feissel; Michel Hasselmann; Alexandra Heininger; Hugo Van Aken Journal: Crit Care Date: 2012-05-24 Impact factor: 9.097
Authors: Nicolai Haase; Anders Perner; Louise Inkeri Hennings; Martin Siegemund; Bo Lauridsen; Mik Wetterslev; Jørn Wetterslev Journal: BMJ Date: 2013-02-15
Authors: Piotr Wittbrodt; Nicolai Haase; Dominika Butowska; Robert Winding; Jesper B Poulsen; Anders Perner Journal: Crit Care Date: 2013-02-25 Impact factor: 9.097
Authors: Martin Kieninger; Daniel Unbekannt; André Schneiker; Barbara Sinner; Sylvia Bele; Christopher Prasser Journal: Neurocrit Care Date: 2017-02 Impact factor: 3.210
Authors: Anders Perner; Anthony C Gordon; Derek C Angus; Francois Lamontagne; Flavia Machado; James A Russell; Jean-Francois Timsit; John C Marshall; John Myburgh; Manu Shankar-Hari; Mervyn Singer Journal: Intensive Care Med Date: 2017-05-12 Impact factor: 17.440
Authors: Anders Perner; Andrew Rhodes; Bala Venkatesh; Derek C Angus; Ignacio Martin-Loeches; Jean-Charles Preiser; Jean-Louis Vincent; John Marshall; Konrad Reinhart; Michael Joannidis; Steven M Opal Journal: Intensive Care Med Date: 2017-01-27 Impact factor: 17.440
Authors: Sofie L Rygård; Lars B Holst; Jørn Wetterslev; Per Winkel; Pär I Johansson; Jan Wernerman; Anne B Guttormsen; Sari Karlsson; Anders Perner Journal: Intensive Care Med Date: 2016-09-30 Impact factor: 17.440